Research Article

Mortality and Cardiovascular Complications in Older Complex Chronic Patients with Type 2 Diabetes

Table 2

Baseline characteristics of CCP patients according to age.

CCP patients <70 years old70–79 years old≥80 years old

(% all)93 (9.97%)184655
Age (average CI 95%)61.39 (59.6–63.1)75.6 (75.2–76.02)87.5 (87.2–87.9)
Women
(% group)
41/93 = 44.08%82 (44.6%)365 (55.7%)
CCP criteria number (average CI 95%)2.9 (2.7–3.22)3.69 (3.5–3.8)4.02 (3.94–4.12)
Diabetes mellitus (% group)53   (57.%)125 (67.9%)16 (48.2%)
Hypertension (% group)63 (67.7%)160 (87.0%)551 (84.1%)
Dyslipidemia (% group)55 (59.1%)125 (67.9%)341 (52.1%)
Atrial fibrillation (% group)17 (18.3%)60 (32.6%)248 (37.9%)
Ischaemic cardiopathy (% group)20 (21.5%)43 (23.4%)133 (20.3%)
Peripheral artery disease (% group)17 (18.3%)41 (22.3%)91 (13.9%)
Chronic kidney insufficiency < 30 mlClCr (% group)12 (12.9%)24 (13.1%)80 (12.2%)
Heart failure (% group) 17/93 = 18.27%53 (28.8%)233 (35.6%)
Charlson score (average CI 95%)2.17 (1.87–2.47)2.7 (2.5–2.9)2.52 (2.42–2.63)
Stroke (% group)21 (22.6%)51 (27.8%)185 (28.3%)
score (average CI 95%)4 (3.11–4.9)5.17 (4.84–5.51)5.03 (4.88–5.20)
Stroke risk/year (average CI 95%)4.78 (3.55–6.02)6.81 (6.2–7.4)6.57 (6.27–6.87)
Daily medications number (average CI 95%)9.21 (8.37–10.6)10.1 (9.5–10.53)8.5 (8.24–8.77)
Cognitive impairment (% group)14 (15.1%)35 (19.0%)289 (44.1%)
Pfeiffer test score (average CI 95%)1.40 (0.86–1.95)1.53 (1.19–1.89)3.71 (3.46–3.97)
Barthel score (average CI 95%)82.8 (77.3–88.4)80.67 (76.9–84.4)59. (57.1–62.08)
Fall risk (% group)5 (5.4%)31 (16.8%)152 (23.2%)
Antiaggregant treatment (% group)30 (32.3%)82 (44.6%)273 (41.7%)
Anticoagulant treatment (% group)25 (26.9%)55 (29.9%)175 (26.7%)
HAS_BLED (average CI 95%)2.93 (2.22–3.65)3.06 (2.81–3.31)2.96 (2.82–3.11)
Bleeding risk/year (average CI 95%)5.18 (3.0–7.37)4.89 (4.0–5.8)4.95 (4.5–5.41)
Statin treatment (% group)54 (58.1%)118 (64.1%)251 (38.3%)
CNS depressant drugs (% group)44 (47.3%)97 (52.7%)373 (56.9%)
Death (% group)12 (12.9%)48 (26.1%)259 (39.5%)
Average follow-up time (days CI 95%)1348 (719–1977)947 (901–993)971 (825–1117)